200 related articles for article (PubMed ID: 23991224)
1. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.
Flågeng MH; Knappskog S; Haynes BP; Lønning PE; Mellgren G
PLoS One; 2013; 8(8):e74618. PubMed ID: 23991224
[TBL] [Abstract][Full Text] [Related]
2. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
[TBL] [Abstract][Full Text] [Related]
3. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
5. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
Pawlowski V; Révillion F; Hebbar M; Hornez L; Peyrat JP
Clin Cancer Res; 2000 Nov; 6(11):4217-25. PubMed ID: 11106235
[TBL] [Abstract][Full Text] [Related]
8. HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue.
Olsen DA; Ostergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Jakobsen A; Brandslund I
Clin Chem Lab Med; 2009; 47(8):977-84. PubMed ID: 19548848
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
10. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
11. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
12. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Flågeng MH; Larionov A; Geisler J; Knappskog S; Prestvik WS; Bjørkøy G; Lilleng PK; Dixon JM; Miller WR; Lønning PE; Mellgren G
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):228-235. PubMed ID: 27343990
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
14. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
15. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
16. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
17. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.
Memon AA; Sorensen BS; Melgard P; Fokdal L; Thykjaer T; Nexo E
Br J Cancer; 2004 Dec; 91(12):2034-41. PubMed ID: 15583696
[TBL] [Abstract][Full Text] [Related]
18. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
